MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 7729-7739

  Wei, Chuankui ^a,b   Luo, Qifeng ^a   Sun, Xiaoguo ^c   Li, Dengfeng ^a   Song, Hongming ^a   Li, Xiaoyu ^a   Song, Jialu ^a   Hua, Kaiyao ^a   Fang, Lin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c Department of General Surgery First People's Hospital of Taian   (China)

Author keywords

Apoptosis; Bcl 2; Breast cancer; MiR 497

Indexed keywords

MICRORNA; MIRN497 MICRORNA, HUMAN; PROTEIN BCL 2;

APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; REPORTER GENE; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 85012960821     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
3. Griffiths-Jones S. Annotating noncoding RNA genes. Annu Rev Genomics Hum Genet 2007; 8: 279-298.
4. Gregory RI and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005; 65: 3509-3512.
5. Vohradsky J, Panek J and Vomastek T. Numerical modelling of microRNA-mediated mRNA decay identifies novel mechanism of microRNA controlled mRNA downregulation. Nucleic Acids Res 2010; 38: 4579-4585.
6. Chu C and Zhao Z. MicroRNA in the molecular mechanism of the circadian clock in mammals. Front Biosci (Landmark Ed) 2013; 18: 441-446.
7. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
9. Shi M and Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009; 35: 328-334.
10. Le Quesne J and Caldas C. Micro-RNAs and breast cancer. Mol Oncol 2010; 4: 230-241.
11. Iorio MV, Casalini P, Tagliabue E, Menard S and Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 2008; 44: 2753-2759.
12. Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI, Prevost GP, Schaapveld RQ and Cuppen E. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One 2012; 7: e43569.
13. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y and Liu P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391.
14. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C and Lui WO. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
15. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH and Langer F. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010; 10: 109.
16. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, Zhao D, Sun Q, Zeng Z, Dress A, Lin MC, Kung HF, Rui H, Liu LZ, Mao F, Jiang BH and Lai L. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17: 1722-1730.
17. Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J and Fang L. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 2012; 3: 475-480.
18. Luo Q, Li X, Gao Y, Long Y, Chen L, Huang Y and Fang L. MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int 2013; 13: 95.
19. Cory S and Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
20. Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DB and Dyer MJ. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood 2008; 111: 874-877.
21. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Muller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM and Chan WC. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968.
22. Skirnisdottir I, Seidal T, Gerdin E and Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002; 12: 265-276.
23. Yanai S, Nakamura S, Takeshita M, Fujita K, Hirahashi M, Kawasaki K, Kurahara K, Sakai Y and Matsumoto T. Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients. Cancer 2011; 117: 2467-2477.
24. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102: 13944-13949.
25. Li L, Yuan L, Luo J, Gao J, Guo J and Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13: 109-117.
26. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J and Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
27. Zhu W, Shan X, Wang T, Shu Y and Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520-2529.
28. Kojima K, Fujita Y, Nozawa Y, Deguchi T and Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010; 70: 1501-1512.
29. Singh R and Saini N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis a combined computational and experimental approach. J Cell Sci 2012; 125: 1568-1578.
30. Yadav S, Pandey A, Shukla A, Talwelkar SS, Kumar A, Pant AB and Parmar D. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem 2011; 286: 37347-37357.
31. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
32. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K and Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and-2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int 2006; 98: 661-667.
33. Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, Huang Y and Fang L. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol 2013; 43: 1212-1218.
34. Li J, Kong X, Zhang J, Luo Q, Li X and Fang L. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int 2013; 13: 7.
35. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.